Long-Acting Monoclonal Antibodies Market Outlook 2025–2032

[Amisha]

The global Long-Acting Monoclonal Antibodies market was valued at USD 18.6 billion in 2024 and is projected to reach USD 52.4 billion by 2032, expanding at a CAGR of 16.3% from 2025 to 2032. This exponential growth is fueled by increasing adoption of biologics, rising prevalence of chronic diseases, and continuous innovations in antibody engineering.

 
Report Sample includes:
- Table of Contents
- List of Tables & Figures
- Charts
- Research Methodology


Get FREE Sample of this Report at https://www.intelmarketresearch.com/download-free-sample/805/global-longacting-monoclonal-antibodies-forecast-2023-2032-169


Long-Acting Monoclonal Antibodies (LA-mAbs) refer to bioengineered antibodies designed with extended half-lives to provide prolonged therapeutic effects. Unlike conventional antibodies that may require frequent administration, LA-mAbs are optimized for infrequent dosing, enhancing patient compliance and treatment efficacy. These biologics are widely used in the treatment of chronic and complex diseases such as cancer, autoimmune disorders, inflammatory conditions, and infectious diseases.

Market Size

In North America, the market was valued at USD 9.8 billion in 2024 and is expected to reach USD 27.2 billion by 2032, at a CAGR of 15.8%, solidifying its dominance due to high healthcare expenditure and early adoption of advanced therapies.

Competitor Analysis

Leading companies are actively investing in clinical trials, strategic collaborations, and new product launches to maintain their market dominance. The top players in the global LA-mAbs market include:

• Eli Lilly
• Abbott Laboratories
• AstraZeneca
• Amgen
• Bayer AG
• Johnson & Johnson
• Pfizer
• GlaxoSmithKline
• Merck
• Novartis

These companies collectively hold a significant revenue share, focusing on therapeutic innovations across cancer, autoimmune, and infectious disease segments.


Get FREE Sample of this Report at https://www.intelmarketresearch.com/download-free-sample/805/global-longacting-monoclonal-antibodies-forecast-2023-2032-169


Market Segmentation (by Type)

• Murine Source
• Chimeric Source
• Human Source

Market Segmentation (by Application)

• Cancer
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Others

Frequently Asked Questions (FAQ

1. What are Long-Acting Monoclonal Antibodies?

Long-Acting Monoclonal Antibodies (LA-mAbs) are engineered antibodies designed to remain active in the body for an extended duration. They provide targeted therapy for various diseases, including cancer, autoimmune disorders, and infectious diseases, reducing the need for frequent dosing.

2. What is the market size of the global Long-Acting Monoclonal Antibodies industry?

As of 2024, the global Long-Acting Monoclonal Antibodies market is valued at USD 18.6 billion and is projected to reach USD 52.4 billion by 2032, growing at a CAGR of 16.3% from 2025 to 2032.

3. Which region is dominating the Long-Acting Monoclonal Antibodies market?

North America is currently the leading region, accounting for a significant share of the global market, with a valuation of USD 9.8 billion in 2024 and projected to grow to USD 27.2 billion by 2032, at a CAGR of 15.8%.

4. What are the key drivers of market growth?

Key drivers include:

• Rising prevalence of chronic diseases
• Increasing demand for long-term, targeted therapies
• Advances in antibody engineering and biopharmaceutical R&D
• Favorable regulatory support and fast-track drug approvals

Get the Complete Report & TOC at https://www.intelmarketresearch.com/life-sciences/805/global-longacting-monoclonal-antibodies-forecast-2023-2032-169

CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: [phone]
Email: [e-mail]

Follow Us On linkedin :- https://www.linkedin.com/company/intelsight-research/

About intel market research :

Established ourselves in the year 2015, Intel Market Reports is a popular market research company that provides an in-depth quantified market research report. The Purpose is to deliver effective and fruit-bearing market research reports. Our portfolio includes the list of 30+ companies belonging to the Fortune 500 list. We have achieved this milestone in less than half a decade.